Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11624195 | 0.83 | LPAR3 (0.41) | CYP4F2CYP4A11 | |
| SCHEMBL11722094 | 0.81 | LPAR3 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL11622847 | 0.77 | CETP (0.33) | — | |
| SCHEMBL11717601 | 0.67 | CYP4F2 (0.39) | CYP4F2CYP4A11 | |
| SCHEMBL11626602 | 0.66 | CYP4F2 (0.41) | CYP4F2CYP4A11 | |
| SCHEMBL10477632 | 0.65 | TSHR (0.37) | — | |
| SCHEMBL4944673 | 0.65 | CYP4F2 (0.36) | CYP4F2CYP4A11 | |
| SCHEMBL17558776 | 0.63 | TSHR (0.36) | — | |
| SCHEMBL28756854 | 0.62 | — | — | |
| SCHEMBL10802478 | 0.61 | CYP4F2 (0.40) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501793-B2 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-7833995-B2 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20070129327-A1 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1707208-A1 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-4208428-A | ANTIFERTILITY, OXYTOCIC | ONO PHARMACEUTICAL CO. LTD. (JP) | 1980-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129327-A1 | Blood flow promoters for cauda equina tissues | PTGFR, PTGIS, PTGIR | CYP4F2 1227/4885CYP4A11 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.